In a syngeneic B16F0 melanoma model and using tyrosinase related protein 1 (TRP1) as a vaccine antigen, it has been found that simultaneous delivery of IL-12 and a PD-L1-silencing shRNA was the only combination that exhibited therapeutically relevant anti-melanoma activities (170). Here, CD274 is linked to melanoma.